Some strong volume movers from Friday I am watching for

New Post Public Reply Private Reply Replies (0) Message Board
Plan
173
Some strong volume movers from Friday I am watching for possible moves or follow through plays next week:

APHD - Strong volume, I like entry on a move above .0014, target .0025,but may run further to .003 or even much better. Wazzzzup spotted this one,so check his posts for more info and his views also.

SBMF - very strong volume, up 200%+ already though. It may continue, entry above .0096 with a tight stop may give a decent play, otherwise waiting for a pullback ,I will watch the rising 9ema on the hourly for an intraday play with a stop below .006. Lots of ways to play this one, make your plans

DTII - Already mentioned by SheepWolf, see his watchlist:
https://investorshangout.com/post/view?id=4623853

EGTYF - .1650-.1675 pullback area looks like a good support area,or a move above Friday's high with a tight stop out for a continuation play. LT breakout support at .0015 IF it ever retest that area.

DEWM - watching the rising 9ema on the hourly and .0075 for a intraday support & bounce play or a move above Friday's high .0084 for a continuation play with a tight stop out. (LT breakout support at .0045-.0050 IF it ever retest).

INNMF - had serious volume come in, spinning top candle indicating indecision,but watching this one for when it decides direction. A move above .60 may send it running.

NPHC - .0012 with .0009 support, massive volume,but in a long term downtrend, worth watching to see if the sellers are finally done here.

KOSK - Is a very low volume play and thus easily manipulated,but I think this one can make a move above .012, position size accordingly as this one may dry up fast and not be easy to get out of. A run to .19 looks like a reasonable target IF it gets going. Support at .008, line in the sand at .006 I personally would play a move above .012 with a tight stop out if it is not working.

*Note-These are only technical setups, there is no DD here as far as financials, news and fundamentals, please do your own review of those areas first. These plans are only a few styles of how I like to play. Keep in mind your own style and only use levels that you understand, believe in and will act decisively on. I play many different ways and across different time frames, one of which is to buy high and sell higher, some call this chasing, but it can be very effective although you MUST respect a failure on a new high move. Failures or (pop & drops) can descend quickly, just get out and ask questions later. GL
The fruits of your success will be in direct ratio to the honesty and sincerity of your own effort in keeping your own records, doing your own thinking and reaching your own conclusions - Jesse Livermore
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 13

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 18

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 19

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 24

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 20

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 24

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 15

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 19

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 19

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Inbank Reports Impressive Growth in Financial Performance

Updated Category News Views 237

Inbank's Stellar Financial Performance in Recent Quarters Inbank has achieved significant milestones in its Q2 2025 financial results, showcasing dynamic growth and resilience in a fluctuating market. The bank reported a remarkable originated volume of 196 million euros, marking a 15% increase from the previous year. Although consolidated net profit saw a slight decline...

Continue Reading
Navient Elects Edward Bramson as Chair After Shareholder Meeting

Updated Category News Views 164

Navient's Annual Meeting Marks a New Chapter HERNDON, Va. - Recently, Navient (Nasdaq: NAVI) convened its Annual Meeting of Shareholders, setting the stage for significant leadership changes within the company. This year, shareholders engaged actively, voting to approve three pivotal proposals outlined by the board of directors. This included the election of seven new...

Continue Reading
Annexon Secures $75 Million in Public Stock Offering

Updated Category News Views 184

Overview of Annexon's Recent Public Offering Annexon, Inc. (NASDAQ: ANNX), a pioneering biopharmaceutical firm, recently announced the successful pricing of its public offering aimed at raising $75 million. This exciting event took place as the company continues to push forward with its mission to address neuroinflammation and related diseases, facilitating groundbreaking...

Continue Reading
Werner Enterprises Set for Key Investment Conferences This Year

Updated Category News Views 310

Werner Enterprises is Poised for Investment Conference Engagements Werner Enterprises, Inc. (Nasdaq: WERN), a well-known name in transportation and logistics, is preparing to participate in several significant investment conferences. These events present a fantastic opportunity for the company to share insights about its growth strategies and market position. Upcoming...

Continue Reading
Cunard Achieves Unprecedented Booking Milestones in 2024

Updated Category News Views 156

Record-Breaking Booking Success for Cunard Cunard has recently announced remarkable booking figures for the year 2024, driven by a stellar year and the eagerly awaited introduction of its ship, Queen Anne. This significant increase has resulted in an astonishing 73,000 more guest reservations from January to October compared to the same timeframe in the previous year,...

Continue Reading